Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Inhibition of tumor necrosis factor improves conventional steroid therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis in a cohort of patients
Suiting Ao, Xuemei Gao, Jipang Zhan, et al.
Journal of the American Academy of Dermatology (2022) Vol. 86, Iss. 6, pp. 1236-1245
Closed Access | Times Cited: 25

Showing 25 citing articles:

Severe cutaneous adverse reactions
Wen‐Hung Chung, Maja Mockenhaupt, Kimberly G. Blumenthal, et al.
Nature Reviews Disease Primers (2024) Vol. 10, Iss. 1
Closed Access | Times Cited: 18
A Review of the Systemic Treatment of Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis
Hua‐Ching Chang, Tsung-Jen Wang, Ming‐Hsiu Lin, et al.
Biomedicines (2022) Vol. 10, Iss. 9, pp. 2105-2105
Open Access | Times Cited: 32
Tumor necrosis factor-α inhibitor for successful treatment of toxic epidermal necrolysis with severe infection: a case series
Yu-Ting Peng, Jianxia Xiong, Bin Wei, et al.
Journal of International Medical Research (2024) Vol. 52, Iss. 1
Open Access | Times Cited: 6
Biologic TNF-α Inhibitors for Stevens–Johnson Syndrome, Toxic Epidermal Necrolysis, and TEN-SJS Overlap: A Study-Level and Patient-Level Meta-Analysis
Jiali Cao, Xuan Zhang, Xinzhu Xing, et al.
Dermatology and Therapy (2023) Vol. 13, Iss. 6, pp. 1305-1327
Open Access | Times Cited: 10
Diagnosing and Managing Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis in Adults: Review of Evidence 2017–2023
S. Oro, I. Matei, Antoine Gaillet, et al.
Journal of Investigative Dermatology (2025)
Closed Access
Stevens‐Johnson Syndrome and Toxic Epidermal Necrolysis: A Review of Current Management and Innovative Therapies
José Dario Martínez, Jesús Alberto Cárdenas‐de la Garza, M Ionescu, et al.
International Journal of Dermatology (2025)
Closed Access
Long-term cardiovascular outcomes among adult survivors of Stevens–Johnson syndrome and toxic epidermal necrolysis: a retrospective cohort study using TriNetX
Sheng-Hsiang Ma, Chun‐Chieh Yeh, Tai‐Li Chen, et al.
Clinical and Experimental Dermatology (2025)
Closed Access
Etanercept treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis
Cuicui Tian, Xuechen Ai, Jianchi Ma, et al.
Annals of Allergy Asthma & Immunology (2022) Vol. 129, Iss. 3, pp. 360-365.e1
Closed Access | Times Cited: 13
Greater mechanistic understanding of the cutaneous pathogenesis of Stevens–Johnson syndrome/toxic epidermal necrolysis can shed light on novel therapeutic strategies: a comprehensive review
Emeka Ogiji, Nourah Aboheimed, Kehinde Ross, et al.
Current Opinion in Allergy and Clinical Immunology (2024) Vol. 24, Iss. 4, pp. 218-227
Open Access | Times Cited: 2
S3 guideline: Diagnosis and treatment of epidermal necrolysis (Stevens‐Johnson syndrome and toxic epidermal necrolysis) – Part 1: Diagnosis, initial management, and immunomodulating systemic therapy
Ruben Heuer, Maren Paulmann, Thorsten Annecke, et al.
JDDG Journal der Deutschen Dermatologischen Gesellschaft (2024) Vol. 22, Iss. 10, pp. 1448-1466
Open Access | Times Cited: 2
APOA4 as a novel predictor of prognosis in Stevens-Johnson syndrome/toxic epidermal necrolysis: A proteomics analysis from two prospective cohorts
Ting Gong, Peng Zhang, Shi‐Fan Ruan, et al.
Journal of the American Academy of Dermatology (2023) Vol. 89, Iss. 1, pp. 45-52
Closed Access | Times Cited: 6
Positive experience with TNF-α inhibitor in toxic epidermal necrolysis resistant to high-dose systemic corticosteroids
Ekaterina A. Nikitina, Daria Fomina, Ulyana A. Mаrkina, et al.
Frontiers in Medicine (2023) Vol. 10
Open Access | Times Cited: 5
A systematic review of case–control studies of cytokines in blister fluid and skin tissue of patients with Stevens Johnson syndrome and toxic epidermal necrolysis
Thomas Stewart, Joshua R. Farrell, John W. Frew
Australasian Journal of Dermatology (2024) Vol. 65, Iss. 6, pp. 491-504
Closed Access | Times Cited: 1
A Bayesian Network Meta-Analysis of the Effect of Targeted Therapies on the Total Length of Hospital Stay in Children with Drug-Induced Stevens–Johnson Syndrome/Toxic Epidermal Necrolysis Syndrome
Sahure ÖZERTÜRK, Didem Derici Yıldırım, Tuğba Arıkoğlu, et al.
Pediatric Allergy Immunology and Pulmonology (2024) Vol. 37, Iss. 1, pp. 22-32
Closed Access | Times Cited: 1
Tumor necrosis factor inhibitors enhance corticosteroid therapy for Stevens-Johnson syndrome and toxic epidermal necrolysis linked to immune checkpoint inhibitors: a prospective study
Chun‐Xia He, Lan Guo, Tao Qu, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 1
Where to place etanercept and combination treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis?
Eric Mukherjee, Elizabeth J. Phillips
Annals of Allergy Asthma & Immunology (2022) Vol. 129, Iss. 3, pp. 269-270
Open Access | Times Cited: 6
Disease severity and status in Stevens–Johnson syndrome and toxic epidermal necrolysis: Key knowledge gaps and research needs
Rannakoe Lehloenya
Frontiers in Medicine (2022) Vol. 9
Open Access | Times Cited: 5
TNF-α Blockade Inhibits Matrix Metalloproteinase 9–Mediated Collagenase Activity in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis
Chun‐Bing Chen, Chuang‐Wei Wang, Wen‐Hung Chung
Journal of Investigative Dermatology (2023) Vol. 143, Iss. 6, pp. 881-883
Open Access | Times Cited: 2
S3‐Leitlinie: Diagnostik und Therapie der epidermalen Nekrolyse (Stevens‐Johnson‐Syndrom und toxisch epidermale Nekrolyse) – Teil 1: Diagnostik, initiales Management und immunmodulierende Systemtherapie
Ruben Heuer, Maren Paulmann, Thorsten Annecke, et al.
JDDG Journal der Deutschen Dermatologischen Gesellschaft (2024) Vol. 22, Iss. 10, pp. 1448-1467
Open Access
Sensory neuroimmune signaling in the pathogenesis of Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN)
Xiaobao Huang, Suiting Ao, Rui Xu, et al.
Journal of Allergy and Clinical Immunology (2024)
Closed Access
Treatment of toxic epidermal necrolysis and concurrent COVID-19-associated hyperinflammatory syndrome with systemic corticosteroids and etanercept
Rachel Choi, James Garritano, Mary Laird, et al.
JAAD Case Reports (2022) Vol. 29, pp. 139-141
Open Access | Times Cited: 2
The activation of AIM2/Caspase-1/GSDMD pathway contributes to pyroptosis of keratinocytes in Stevens-Johnson syndrome/toxic epidermal necrolysis
Lu Yang, Yanhong Shou, Feng Li, et al.
Research Square (Research Square) (2023)
Open Access
JAAD Game Changer: Inhibition of tumor necrosis factor improves conventional steroid therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis in a cohort of patients
Wendi Wohltmann
Journal of the American Academy of Dermatology (2023) Vol. 90, Iss. 5, pp. 1114-1114
Closed Access
Hospital Dermatology: Review of Research in 2022-2023
Juliana Berk-Krauss
Cutis (2023) Vol. 112, Iss. 5
Open Access
Quoi de neuf en thérapeutique dermatologique ?
O. Dereure
Annales de Dermatologie et de Vénéréologie - FMC (2022) Vol. 2, Iss. 8, pp. 2/8S101-2/8S109
Closed Access
Page 1

Scroll to top